1 year ago when I spoke to Dr Elizabeth she was optimistic with "caution" around the failed Novartis trial. She said that many trials have failed and that we should not pin extreme optimism on this one.
Today here words are
Elizabeth Berry-Kravis MD, PhD, Professor of Pediatrics, Neurology and Biochemistry at Rush University Medical Center, has directed the Fragile X Clinic and Research Program at Rush since 1992. She commented: “This was the first industry-sponsored study to look at a full range of meaningful symptoms using a number of Fragile X-specific outcome measures. The results are very encouraging and fully support moving to the next step in development. The design and analyses were both innovative and appropriate for this proof of concept trial. ”
Thank you Dr Berry-Kravis.
Ann: Trofinetide successful in Phase 2 trial in Fragile X, page-7
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.30 |
Change
1.030(8.39%) |
Mkt cap ! $1.699B | |||
| Open | High | Low | Value | Volume |
| $12.95 | $13.36 | $12.79 | $7.442M | 569.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 144 | $13.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.32 | 1124 | 6 |
View Market Depth
| Last trade - 15.17pm 06/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |